

Notice of Changes to 340B Prices
September 19, 2023

Pursuant to 42 C.F.R. § 447.510(b), Eli Lilly and Company (Lilly) has submitted routine updated 2Q2020 Average Manufacturer Prices and Best Prices for certain of its covered outpatient drugs to the Centers for Medicare & Medicare Services (CMS) to account for lagged transactional data. These restated Medicaid prices result in both upward and downward adjustments to 4Q2020 340B Ceiling Prices.

Table 1: Products Subject to Upward Adjustments to the Previously Reported Ceiling Price

NDC	Product Description
00002764001	ALIMTA 100 MG 1.000000 VIAL
00002762301	ALIMTA 500 MG 1.000000 VIAL
66733095823	ERBITUX 200 MG 100.000000 MILLILITER
00002831501	HUMULIN N 100UCD 10.000000 MML

Lilly has elected not to seek recoupment of these underpayments from Covered Entities.

Table 2: Products Subject to Downward Adjustments to the Previously Reported Ceiling Price

NDC	Product Description
00002814801	HUMATROPE 12 MG 1.000000 MILLILITER
00002814701	HUMATROPE 6 MG 1.000000 MILLILITER
00002880559	HUMULIN N PEN 100UCD 15 MILLILITER

Lilly uses wholesaler chargeback records to calculate and automatically issue refund payments to impacted eligible Covered Entities at the address listed in the HRSA database.

Lilly does not directly contact or automatically issue checks to Covered Entities who may be eligible for amounts less than \$1.00 resulting from this restatement. For these de minimis changes, Lilly is offering to refund such Covered Entities through this Notice.

Covered Entities who believe they may be entitled to a refund amount less than \$1.00 for purchases of the above listed products in 4Q2020 or have questions about refunds Lilly already issued may contact Lilly at basesupport_cma@lilly.com with "Attn: 340B Recalculation" in the subject line to confirm any applicable amounts at issue and to initiate the payment process.

Lilly has requested that the Health Resource and Services Administration (HRSA) post this Notice on the HRSA public website to ensure transparency to Covered Entities regarding Lilly's recalculation and refund process.
